This article is more than 5 years old. Information may no longer be current.
AbbVie reports worldwide Q3 sales up 7.8%
Click Here to Manage Email Alerts
AbbVie announced its financial results for the third quarter ended Sept. 30, which included a 7.8% increase in worldwide sales to $5.019 billion.
Third-quarter global sales growth was propelled substantially by Humira (adalimumab), with an increase of 17.5%, or 17.8% on an operational basis, according to a company press release.
AbbVie also reported third-quarter diluted earnings per share of $0.31 on a GAAP basis. Adjusted earnings per share were $0.89, marking an increase of 8.5% from the previous year and an amount well above the previous guidance range of $0.77 to $0.79, according to the release.
AbbVie raised its adjusted diluted earnings per share guidance range for 2014 to $3.25 to $3.27 from $3.06 to $3.16, excluding any potential revenue from HCV, according to the press release.